Pratap Shankar K M, Pratibha P Nair, Saritha V
National Ayurveda Research Institute for Panchakarma, Cheruthuruthy, Thrissur, Kerala, India.
Department Of Kayachikitsa, VPSV Ayurveda College, Kottakkal, Kerala, India.
J Ayurveda Integr Med. 2023 May-Jun;14(3):100737. doi: 10.1016/j.jaim.2023.100737. Epub 2023 Jun 8.
The world witnessed much research fund allocation on the COVID-19 outbreak's epidemiology, pathology, impact on lifestyles, social behaviours and treatment possibilities. The highly contagious nature of the disease compelled scientific communities and related organisations to hasten vaccine development and supplies. Well-timed international collaborations resulted in quicker development of varied forms of vaccines against COVID-19. Prospective observational studies and systematic reviews on vaccine trials reported their safety and efficacies. Nevertheless, post-marketing surveillance is quintessential to ascertain such safety and efficacy claims. There have been scattered reports lately of several adverse temporal events, such as haematological, immunological and neurological untoward occurrences following COVID-19 inoculation. There is a growing piece of evidence of the impact of COVID vaccination on patients with neurological-neuroimmunological disorders. Here two unrelated cases of neurological deficits post-COVID vaccination are reported. One was an incidence of Acute Disseminated Encephalomyelitis, while the other was an acute exacerbation of Multiple Sclerosis following vaccination. Ayurvedic treatments were effective in either of these conditions. Case series and case reports shall judiciously add information to vaccine safety data and acknowledge the necessity of clinician approval, based on detailed individualised assessments before mass vaccination.
全世界目睹了在新冠疫情的流行病学、病理学、对生活方式、社会行为的影响以及治疗可能性方面投入了大量研究资金。该疾病的高传染性促使科学界和相关组织加快疫苗研发和供应。及时的国际合作使得针对新冠病毒的多种形式疫苗得以更快研发出来。关于疫苗试验的前瞻性观察研究和系统评价报告了它们的安全性和有效性。然而，上市后监测对于确定此类安全性和有效性声明至关重要。最近有零散报道称，接种新冠疫苗后出现了一些不良的时间性事件，如血液学、免疫学和神经系统的不良情况。越来越多的证据表明新冠疫苗接种对患有神经 - 神经免疫疾病的患者有影响。在此报告两例接种新冠疫苗后出现神经功能缺损的不相关病例。一例是急性播散性脑脊髓炎，另一例是接种疫苗后多发性硬化症的急性加重。阿育吠陀疗法在这两种情况下均有效。病例系列和病例报告应审慎地为疫苗安全数据增添信息，并基于大规模接种前详细的个体化评估，承认临床医生批准的必要性。
